Literature DB >> 24804834

Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders.

Trevor Archer1, Serafino Ricci, Danilo Garcia, Max Rapp Ricciardi.   

Abstract

The neurodegenerative and neurotoxic aspects of schizophrenia and/or psychosis involve genetic, epigenetic, and neurotoxic propensities that impinge upon both the symptom domains and the biomarkers of the disorder, involving cellular apoptosis/excitotoxicity, increased reactive oxygen species formation, viral and bacterial infections, anoxic birth injury, maternal starvation, drugs of abuse, particularly cannabis, metabolic accidents, and other chemical agents that disrupt normal brain development or the integrity of brain tissues. Evidence for premorbid and prodromal psychotic phases, aspects of neuroimaging, dopamine, and psychosis vulnerability, and perinatal aspects provide substance for neurodegenerative influences. Not least, the agencies of antipsychotic contribute to the destructive spiral that disrupts normal structure and function. The etiopathogenesis of psychosis is distinguished also by disruptions of the normal functioning of the neurotrophins, in particular brain-derived neurotrophic factor, dyskinesic aspects, immune system disturbances, and metabolic aspects. Whether detrimental to neurodevelopment or tissue-destructive, or an acceleration of neurotoxic pathways, the notion of neurodegeneration in the pathophysiology of schizophrenia spectrum and psychotic disorders continues to gather momentum.

Entities:  

Mesh:

Year:  2014        PMID: 24804834     DOI: 10.1007/s12640-014-9473-0

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  188 in total

1.  Saitohin polymorphism and executive dysfunction in schizophrenia.

Authors:  Marta Bosia; Mariachiara Buonocore; Carmelo Guglielmino; Adele Pirovano; Cristina Lorenzi; Alessandra Marcone; Placido Bramanti; Stefano F Cappa; Eugenio Aguglia; Enrico Smeraldi; Roberto Cavallaro
Journal:  Neurol Sci       Date:  2011-12-21       Impact factor: 3.307

2.  Cingulate volume abnormalities in emerging psychosis.

Authors:  Michel Röthlisberger; Anita Riecher-Rössler; Jacqueline Aston; Paolo Fusar-Poli; Ernst-Wilhelm Radü; Stefan Borgwardt
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene.

Authors:  Mirjana Tosic; Jurg Ott; Sandra Barral; Pierre Bovet; Patricia Deppen; Fulvia Gheorghita; Marie-Louise Matthey; Josef Parnas; Martin Preisig; Michael Saraga; Alessandra Solida; Sally Timm; August G Wang; Thomas Werge; Michel Cuénod; Kim Quang Do
Journal:  Am J Hum Genet       Date:  2006-07-31       Impact factor: 11.025

Review 4.  Dopaminergic mechanisms in idiopathic and drug-induced psychoses.

Authors:  J A Lieberman; B J Kinon; A D Loebel
Journal:  Schizophr Bull       Date:  1990       Impact factor: 9.306

5.  Gender-specific COMT Val158Met polymorphism association in Spanish schizophrenic patients.

Authors:  Janet Hoenicka; Elena Garrido; Isabel Martínez; Guillermo Ponce; María Aragüés; Roberto Rodríguez-Jiménez; Laura España-Serrano; Ximena Alvira-Botero; José Luis Santos; Gabriel Rubio; Miguel Angel Jiménez-Arriero; Tomás Palomo
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-01-05       Impact factor: 3.568

Review 6.  Role of tau protein in both physiological and pathological conditions.

Authors:  Jesus Avila; Jose J Lucas; Mar Perez; Felix Hernandez
Journal:  Physiol Rev       Date:  2004-04       Impact factor: 37.312

7.  3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia.

Authors:  Philip Tibbo; Chris Hanstock; Agitha Valiakalayil; Peter Allen
Journal:  Am J Psychiatry       Date:  2004-06       Impact factor: 18.112

8.  Schizophrenia induces oxidative stress and cytochrome C release in isolated rat brain mitochondria: a possible pathway for induction of apoptosis and neurodegeneration.

Authors:  Mehrdad Faizi; Ahmad Salimi; Motahareh Rasoulzadeh; Parvaneh Naserzadeh; Jalal Pourahmad
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

9.  Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies.

Authors:  P Fusar-Poli; R Smieskova; M J Kempton; B C Ho; N C Andreasen; S Borgwardt
Journal:  Neurosci Biobehav Rev       Date:  2013-06-14       Impact factor: 8.989

10.  Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis.

Authors:  V A Morgan; J J McGrath; A Jablensky; J C Badcock; A Waterreus; R Bush; V Carr; D Castle; M Cohen; C Galletly; C Harvey; B Hocking; P McGorry; A L Neil; S Saw; S Shah; H J Stain; A Mackinnon
Journal:  Psychol Med       Date:  2013-12-23       Impact factor: 7.723

View more
  5 in total

Review 1.  Physical Exercise Alleviates Health Defects, Symptoms, and Biomarkers in Schizophrenia Spectrum Disorder.

Authors:  Trevor Archer; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-07-15       Impact factor: 3.911

2.  Psychosis in Machado-Joseph Disease: Clinical Correlates, Pathophysiological Discussion, and Functional Brain Imaging. Expanding the Cerebellar Cognitive Affective Syndrome.

Authors:  Pedro Braga-Neto; José Luiz Pedroso; Ary Gadelha; Maura Regina Laureano; Cristiano de Souza Noto; Griselda Jara Garrido; Orlando Graziani Povoas Barsottini
Journal:  Cerebellum       Date:  2016-08       Impact factor: 3.847

3.  Total Tau and Phosphorylated Tau Protein Serum Levels in Patients with Schizophrenia Compared with Controls.

Authors:  Ömer Faruk Demirel; Ihsan Cetin; Şenol Turan; Nazım Yıldız; Tarık Sağlam; Alaattin Duran
Journal:  Psychiatr Q       Date:  2017-12

4.  Correlations of Kynurenic Acid, 3-Hydroxykynurenine, sIL-2R, IFN-α, and IL-4 with Clinical Symptoms During Acute Relapse of Schizophrenia.

Authors:  Kinga Szymona; Barbara Zdzisińska; Hanna Karakuła-Juchnowicz; Tomasz Kocki; Martyna Kandefer-Szerszeń; Marta Flis; Wojciech Rosa; Ewa M Urbańska
Journal:  Neurotox Res       Date:  2017-03-08       Impact factor: 3.911

5.  Increased serum levels of apoptosis in deficit syndrome schizophrenia patients: a preliminary study.

Authors:  Murat Beyazyüz; Tarkan Küfeciler; Leyla Bulut; Cüneyt Ünsal; Yakup Albayrak; Esra Soydaş Akyol; Saliha Baykal; Murat Kuloglu; Kenji Hashimoto
Journal:  Neuropsychiatr Dis Treat       Date:  2016-05-23       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.